Join Dr. Monique Hartley-Brown, a Black myeloma specialist as she shares why the Black community should care about the myeloma PROMISE study. It’s the first study to test those who identify as Black or African American who may be at risk for the multiple myeloma precursor condition Monoclonal Gammopathy of Undetermined Significance (MGUS). The study aims to make multiple myeloma a preventable cancer.
Let's spread the word about this easy-to-manage at-home study so we can better understand what is driving myeloma growth and what the Black Myeloma Community can do to prevent it.
“I became a Myeloma Coach after meeting many patients who did not have a peer mentor to ask questions and find relevant information about myeloma.”
Dr. Hartley-Brown is an emerging national leader in the field of Multiple Myeloma. She is an attending Medical Oncologist who specializes in treating patients with multiple myeloma. She practices clinical care at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. Multiple myeloma is an incurable cancer that affects Black Americans approximately twice more than Caucasians. Dr. Hartley-Brown has written several publications and has been a clinical research investigator for numerous clinical studies that has contributed to the advancement of clinical care for patients with multiple myeloma and plasma cell dyscrasias. As a Black female physician, she is dedicated to ensuring that the care for the myeloma community is equitable and affords all patients with myeloma an optimal level of care regardless of background, race or socioeconomic status. Some of her accolades include being a prior recipient of the John W.V. Cordice, Sr., Honors award in 2004 from New York University School of Medicine, recipient of the K30 Scholarship award for research and career development in 2008 from the University of South Florida, and recipient of the Fellow Scholarship award in 2010 from American Society of Oncology (ASCO). She remains actively involved within the American Society of Hematology (ASH) as an ambassador, mentor and grant reviewer. She is also very active within the Alliance for clinical trials, as a member of the Multiple Myeloma committee, dedicated to working within the consortium to advance clinical trials and novel therapies for advancing treating outcomes for patients with multiple myeloma.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113